Hanmi Pharm. Co., Ltd. (KRX: 128940)

Market Cap	3.61T
Revenue (ttm)	1.57T
Net Income (ttm)	184.38B
Shares Out	12.68M
EPS (ttm)	14,533.91
PE Ratio	19.61
Forward PE	19.71
Dividend	500.00 (0.17%)
Ex-Dividend Date	Jun 27, 2024

Volume	65,403
Open	283,000
Previous Close	289,500
Day's Range	276,500 - 290,000
52-Week Range	258,000 - 377,000
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2024

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,273
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2023, Hanmi Pharm.'s revenue was 1.49 trillion, an increase of 11.97% compared to the previous year's 1.33 trillion. Earnings were 146.23 billion, an increase of 76.63%.